>
Switch to:

Allergy Therapeutics Change In Receivables

: $3.2 Mil (TTM As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Allergy Therapeutics's change in receivables for the quarter that ended in Jun. 2021 was $8.2 Mil. It means Allergy Therapeutics's Accounts Receivable declined by $8.2 Mil from Dec. 2020 to Jun. 2021 .

Allergy Therapeutics's change in receivables for the fiscal year that ended in Jun. 2021 was $3.0 Mil. It means Allergy Therapeutics's Accounts Receivable declined by $3.0 Mil from Jun. 2020 to Jun. 2021 .

Allergy Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2021 was $4.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Allergy Therapeutics's Days Sales Outstanding for the six months ended in Jun. 2021 was 17.83.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Allergy Therapeutics's liquidation value for the six months ended in Jun. 2021 was $11.7 Mil.


Allergy Therapeutics Change In Receivables Historical Data

The historical data trend for Allergy Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Change In Receivables
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 4.39 -2.36 4.62 3.00

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Change In Receivables Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.74 -0.23 4.85 -4.98 8.19

Allergy Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was $3.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Allergy Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2021 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=4.1514726507714/42.495091164095*91
=17.83

2. In Ben Graham's calculation of liquidation value, Allergy Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Allergy Therapeutics's liquidation value for the quarter that ended in Jun. 2021 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=56.483870967742-55.475455820477+0.75 * 4.1514726507714+0.5 * 15.200561009818
=11.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)